CCO
0.003
50%
FIN
0.005
-28.6%
M2R
0.003
50%
CAN
0.003
-25%
SPX
0.003
50%
KTA
0.004
-20%
TOU
0.003
50%
VIT
0.021
-19.2%
UM1
0.165
37.5%
AVD
0.1
-16.7%
AVE
0.02
33.3%
ENL
0.005
-16.7%
BLU
0.004
33.3%
FEL
0.005
-16.7%
HIQ
0.008
33.3%
IPD
0.005
-16.7%
LKO
0.64
25.5%
BNL
0.006
-14.3%
M2M
0.01
25%
KM1
0.09
-14.3%
MGU
0.005
25%
LIS
0.12
-14.3%
PL9
0.007
16.7%
PET
0.006
-14.3%
SIS
0.007
16.7%
BAK
0.16
-13.5%
YAR
0.007
16.7%
CRD
0.415
-13.5%
BNZ
2.47
16.5%
AAU
0.007
-12.5%
ZNO
0.058
16%
CYP
0.014
-12.5%
SIX
0.081
15.7%
MQR
0.007
-12.5%
PKY
0.059
15.7%
WOA
0.007
-12.5%
MEL
0.016
14.3%
KLV
0.067
-11.8%
PV1
0.008
14.3%
TAS
0.053
-11.7%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

BOT successful completion of human factors validation study

Clinical dermatology company Botanix Pharmaceuticals (ASX:BOT) announces that the Company has successfully completed the planned human factors validation study assessing the revised Instructions for Use for Sofpironium Bromide gel https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02753854-6A1186430 #shorts